Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe

The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey SAN DIEGO, March 15, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ:ILMN) today announced the launch of TruSightâ„¢ Oncology (TSO)…

Click here to view original post